Jump to main content
Jump to site search

Issue 45, 2016, Issue in Progress
Previous Article Next Article

Fullerenol nanoparticles as a new delivery system for doxorubicin

Author affiliations


Doxorubicin is a very potent chemotherapeutic drug, however its side effects limit its clinical use. The aim of this research was to investigate the properties of a fullerenol/doxorubicin nanocomposite, its potentially cytotoxic and genotoxic effects on malignant cell lines, as well as its toxicity towards zebra fish embryos. Chromatographic, NMR and mass spectral analysis of the nanocomposite imply that interactions between doxorubicin and fullerenol are non-covalent bonds. The stability of the nanocomposite was confirmed by the use of atomic force microscopy, dynamic light scattering and transmission electron microscopy. The nanocomposite, compared to the free doxorubicin at equivalent concentrations, significantly decreased the viability of MCF-7 and MDA-MB-231 cells. The flow cytometry results indicated that doxorubicin-loaded fullerenol could remarkably increase the uptake of doxorubicin suggesting that fullerenol might be a promising intracellular targeting carrier for the efficient delivery of antitumor drugs into tumor cells. The nanocomposite also affected cell cycle distribution. A genotoxicity test showed that the nanocomposite at all examined concentrations on MCF-7 and at lower concentrations on MDA-MB-231 cells caused DNA damage. Consequently, cell proliferation was notably reduced when compared with controls. Results of the zebrafish embryotoxicity assay showed a decreased overall toxicity, particularly cardiotoxicity and increased safety of the nanocomposite in comparison to doxorubicin alone, as manifested by a higher survival of embryos and less pericardial edema.

Graphical abstract: Fullerenol nanoparticles as a new delivery system for doxorubicin

Back to tab navigation

Supplementary files

Publication details

The article was received on 11 Feb 2016, accepted on 13 Apr 2016 and first published on 14 Apr 2016

Article type: Paper
DOI: 10.1039/C6RA03879D
Citation: RSC Adv., 2016,6, 38563-38578

  •   Request permissions

    Fullerenol nanoparticles as a new delivery system for doxorubicin

    D. S. Jović, M. N. Seke, A. N. Djordjevic, J. Ž. Mrđanović, L. D. Aleksić, G. M. Bogdanović, A. B. Pavić and J. Plavec, RSC Adv., 2016, 6, 38563
    DOI: 10.1039/C6RA03879D

Search articles by author